259 related articles for article (PubMed ID: 32503957)
21. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
[TBL] [Abstract][Full Text] [Related]
22. The roles of prostate-specific antigen (PSA) density, prostate volume, and their zone-adjusted derivatives in predicting prostate cancer in patients with PSA less than 20.0 ng/mL.
Shen P; Zhao J; Sun G; Chen N; Zhang X; Gui H; Yang Y; Liu J; Shu K; Wang Z; Zeng H
Andrology; 2017 May; 5(3):548-555. PubMed ID: 28409907
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer antigen-3 (PCA3) and PCA3-based nomograms in the diagnosis of prostate cancer: an external validation of Hansen's nomogram on a Norwegian cohort.
Nygård Y; Haukaas SA; Eide GE; Halvorsen OJ; Gravdal K; Frugård J; Akslen LA; Beisland C
Scand J Urol; 2015 Feb; 49(1):8-15. PubMed ID: 25141128
[TBL] [Abstract][Full Text] [Related]
24. External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers.
Cindolo L; Bertolo R; Minervini A; Sessa F; Muto G; Bove P; Vittori M; Bozzini G; Castellan P; Mugavero F; Falsaperla M; Schips L; Celia A; Bada M; Porreca A; Pastore A; Al Salhi Y; Giampaoli M; Novella G; Rizzetto R; Trabacchin N; Mantica G; Pini G; Lombardo R; Tubaro A; Antonelli A; De Nunzio C
World J Urol; 2020 Oct; 38(10):2555-2561. PubMed ID: 31907633
[TBL] [Abstract][Full Text] [Related]
25. Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool.
Lee SM; Liyanage SH; Wulaningsih W; Wolfe K; Carr T; Younis C; Van Hemelrijck M; Popert R; Acher P
Urol Oncol; 2017 Nov; 35(11):664.e11-664.e18. PubMed ID: 28801025
[TBL] [Abstract][Full Text] [Related]
26. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
[TBL] [Abstract][Full Text] [Related]
27. A Radiomics nomogram for predicting bone metastasis in newly diagnosed prostate cancer patients.
Zhang W; Mao N; Wang Y; Xie H; Duan S; Zhang X; Wang B
Eur J Radiol; 2020 Jul; 128():109020. PubMed ID: 32371181
[TBL] [Abstract][Full Text] [Related]
28. Construction and Validation of a Clinical Predictive Nomogram for Improving the Cancer Detection of Prostate Naive Biopsy Based on Chinese Multicenter Clinical Data.
Tao T; Wang C; Liu W; Yuan L; Ge Q; Zhang L; He B; Wang L; Wang L; Xiang C; Wang H; Chen S; Xiao J
Front Oncol; 2021; 11():811866. PubMed ID: 35127526
[TBL] [Abstract][Full Text] [Related]
29. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
[TBL] [Abstract][Full Text] [Related]
30. External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection.
Gandaglia G; Martini A; Ploussard G; Fossati N; Stabile A; De Visschere P; Borgmann H; Heidegger I; Steinkohl F; Kretschmer A; Marra G; Mathieu R; Surcel C; Tilki D; Tsaur I; Valerio M; Van den Bergh R; Ost P; Gontero P; Montorsi F; Briganti A;
Eur Urol; 2020 Aug; 78(2):138-142. PubMed ID: 32268944
[TBL] [Abstract][Full Text] [Related]
31. Development and internal validation of a novel PHI-nomogram to identify aggressive prostate cancer.
Foj L; Filella X
Clin Chim Acta; 2020 Feb; 501():174-178. PubMed ID: 31758936
[TBL] [Abstract][Full Text] [Related]
32. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy.
Lughezzani G; Lazzeri M; Larcher A; Lista G; Scattoni V; Cestari A; Buffi NM; Bini V; Guazzoni G
J Urol; 2012 Oct; 188(4):1144-50. PubMed ID: 22901589
[TBL] [Abstract][Full Text] [Related]
33. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients.
Suzuki H; Komiya A; Kamiya N; Imamoto T; Kawamura K; Miura J; Suzuki N; Nakatsu H; Hata A; Ichikawa T
Urology; 2006 Jan; 67(1):131-6. PubMed ID: 16413348
[TBL] [Abstract][Full Text] [Related]
34. Nomogram for prediction of prostate cancer with serum prostate specific antigen less than 10 ng/mL.
Ahn JH; Lee JZ; Chung MK; Ha HK
J Korean Med Sci; 2014 Mar; 29(3):338-42. PubMed ID: 24616581
[TBL] [Abstract][Full Text] [Related]
35. Exploration of the diagnostic capacity of PSAMR combined with PI-RADS scoring for clinically significant prostate cancer and establishment and validation of the Nomogram prediction model.
Li D; Zhang L; Xu Y; Wu X; Hua S; Jiang Y; Huang Q; Gao Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11309-11317. PubMed ID: 37365430
[TBL] [Abstract][Full Text] [Related]
36. Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy.
Cormio L; Cindolo L; Troiano F; Marchioni M; Di Fino G; Mancini V; Falagario U; Selvaggio O; Sanguedolce F; Fortunato F; Schips L; Carrieri G
Front Oncol; 2018; 8():438. PubMed ID: 30386737
[TBL] [Abstract][Full Text] [Related]
37. [Development of a Chinese nomogram based on muti-parametric magnetic resonance for predicting the probability of prostate cancer in patients after initial negative biopsy].
Huang C; Ji GJ; Song G; Wang H; Chen YK; Zhou LQ
Zhonghua Yi Xue Za Zhi; 2018 Jan; 98(2):132-135. PubMed ID: 29343039
[No Abstract] [Full Text] [Related]
38. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
39. Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.
Rubio-Briones J; Borque A; Esteban LM; Casanova J; Fernandez-Serra A; Rubio L; Casanova-Salas I; Sanz G; Domínguez-Escrig J; Collado A; Gómez-Ferrer A; Iborra I; Ramírez-Backhaus M; Martínez F; Calatrava A; Lopez-Guerrero JA
BMC Cancer; 2015 Sep; 15():633. PubMed ID: 26362197
[TBL] [Abstract][Full Text] [Related]
40. Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms.
Stephan C; Siemssen K; Cammann H; Friedersdorff F; Deger S; Schrader M; Miller K; Lein M; Jung K; Meyer HA
Clin Chem; 2011 Jul; 57(7):995-1004. PubMed ID: 21610217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
